Founded in 2015 and based in South San Francisco, we are a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. We are translating our innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in three Phase 2 trials across five se...
Founded in 2015 and based in South San Francisco, we are a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. We are translating our innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in three Phase 2 trials across five separate autoimmune diseases of high unmet need - lupus nephritis, dermatomyositis/polymyositis, and autoimmune hemolytic anemia/immune thrombocytopenia.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.